ACN secures funding for Circulogene

ACN secures funding for Circulogene

Alabama Capital Network Secures
Series B Funding Round for Birmingham-Based CIRCULOGENE


New funding supports product, sales territory and scientific research expansion


BIRMINGHAM, Ala. – Members of the Alabama Capital Network (ACN) – a group of top businesses and investors supporting the state’s innovation sector – contributed to the majority of Series B funding for pioneering molecular genetics testing company CIRCULOGENE. This financing will support CIRCULOGENE’s continued growth as it expands product offerings, broadens sales territories and publishes more research.


“The Alabama Capital Network and its members are impressed with the progress made by CIRCULOGENE and excited at the promise it holds in the oncology realm,” said Alabama Capital Network CEO, Miller Girvin. “All of us have been impacted by cancer at some level, and the ability of CIRCULOGENE’s technology to monitor a diagnosis with a tiny tube of blood shows us where health care is headed.”


Founded in 2016 by President and CEO Mike Mullen, Chief Operating Officer Scott Rezek and Chief Scientific Officer Chen-Hsiung Yeh, Ph.D., CIRCULOGENE provides advanced genomic analysis of tumor mutations for oncology clinics across the U.S. and parts of Europe and the Middle East. The company’s laboratory supports an industry-leading three-day turnaround-time capability for all DNA, RNA and immunotherapy test results at a fraction of current industry costs. “This infusion of capital will support our lab’s advanced testing capabilities and growing demand for our proprietary, direct-on-specimen, nucleic-acid enrichment technology as we scale our operations in the cancer diagnostics market,” said CIRCULOGENE President and CEO Mike Mullen.


To learn more about CIRCULOGENE, please visit To learn more about the Alabama Capital Network, visit




Headquartered in Birmingham, Ala., CIRCULOGENE is an innovative molecular diagnostics company founded and operated by a team of experienced industry executives and skilled molecular diagnostics scientists. Applying its proprietary laboratory developed test for cfDNA, cfRNA and MSI liquid biopsies, CIRCULOGENE has developed the next-generation sequencing (NGS) method to provide full genomic load analysis from one standard tube of blood and in less than seven days, enabling more accurate data to help clinicians and their patients choose targeted therapies, monitor efficacy and monitor for recurrence. For more information, visit or call 855-614-7083.


About Alabama Capital Network The Alabama Capital Network (“ACN”), founded in 2017, is a community economic development organization whose mission is to raise awareness of and contribute to the growth of the entrepreneurial ecosystem in Alabama. ACN is a network that facilitates connections among entrepreneurs, investors, advisors, service providers and corporations to bridge the funding gap faced by Alabama companies in the early growth phase of business. Learn more at